Capsular polysaccharide immunomodulator
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsArthur O. Tzianabos, Andrew B. Onderdonk, Dennis L. Kasper
Life of this patent
Estimating the term…
Abstract
Methods and products for protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. Methods for forming immunomodulators and pharmaceutical compositions relating thereto also are provided. The products useful in the invention are polysaccharides including a repeat unit having a positively charged free amino group and a negatively charged group. The preferred polysaccharide is B. fragilis capsular polysaccharide A.
Claims31
A method for inducing protection against abscess formation associated with infection comprising:
- administering to a subject in need of such protection a pharmaceutical preparation containing an effective amount, for inducing protection against abscess formation, of a polysaccharide formed of repeating units with each repeating unit being formed of a maximum of ten monosaccharides, wherein each repeating unit includes a free amino moiety and a negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate, and wherein the polysaccharide is free from dimerization as part of a B. fragilis capsular polysaccharide complex.
A method for preparing a pharmaceutical for inducing protection against abscess formation associated with infection comprising:
- selecting a polysaccharide formed of repeating units with each repeating unit being formed of a maximum of ten monosaccharides, each repeating unit having at least one negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate, and having at least one N-acetyl moiety;
- de-N-acetylating the polysaccharide to convert said at least one N-acetyl moiety of each repeating unit to a free amino moiety;
- and
- mixing the de-N-acetylated polysaccharide with a pharmaceutically acceptable carrier.
A method for preparing a pharmaceutical for inducing protection against abscess formation associated with infection comprising:
- selecting a polysaccharide formed of repeating units with each repeating unit being formed of a maximum of ten monosaccharides, each repeating unit having at least one negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate, and having at least one imine group;
- reducing the polysaccharide to convert the at least one imine group of each repeating unit to a free amino moiety;
- and
- mixing the reduced polysaccharide with a pharmaceutically acceptable carrier.
A pharmaceutical preparation which induces protection against abscess formation comprising:
- a pharmaceutically effective amount, for inducing protection against abscess formation, of a polysaccharide consisting essentially of a plurality of a repeating unit, with each repeating unit being formed of a maximum of ten monosaccharides, each repeating unit including a free amine moiety and a negatively charged moiety, selected from the group consisting of carboxyl, phosphate and phosphonate;
- and
- a pharmaceutically acceptable carrier, wherein said polysaccharide is free from dimerization as part of a B. fragilis polysaccharide complex and said polysaccharide is not selected from the group consisting of Streptococcus pneumoniae polysaccharide, Trypanosoma cruzi lipopeptidophosphoglycan and Pseudomonas aeurignosa Fisher immunotype 7O-antigen.
A pharmaceutical preparation which induces protection against abscess formation comprising:
- a pharmaceutically effective amount, for inducing protection against abscess formation, of a polysaccharide;
- and
- a pharmaceutically acceptable carrier, wherein the polysaccharide was prepared by the process of de-N-acetylation of a precursor polysaccharide that consists essentially of a plurality of a precursor repeating unit, to produce a plurality of a precursor repeating unit with each modified repeating unit having at least one N-acetyl moiety and one negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate, wherein at least one N-acetyl moiety is de-N-acetylated to form a free amino moiety.
A pharmaceutical preparation which induces protection against abscess formation comprising:
- a pharmaceutically effective amount, for inducing protection against abscess formation, of a polysaccharide;
- and
- a pharmaceutically acceptable carrier, wherein the polysaccharide was prepared by the process of reducing a precursor polysaccharide that consists essentially of a plurality of a precursor repeating unit, to produce a plurality of a modified repeating unit with each precursor repeating unit having at least one imine moiety and one negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate, wherein at least one imine moiety is reduced to form a free amino moiety.
A pharmaceutical preparation which induces protection against abscess formation comprising:
- a pharmaceutically effective amount, for inducing protection against abscess formation, of a polysaccharide formed of repeating units of a maximum of ten monosaccharides with each repeating unit including a free amino moiety and a negatively charged moiety selected from the group consisting of carboxyl, phosphate and phosphonate and wherein said polysaccharide is free of dimerization as part of a B. fragilis polysaccharide complex;
- a cytokine that enhances T-cell response and is free of B-cell enhancing activity;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.